tazemetostat – Patient Worthy

$Priority Review Granted for Relapsed and Refractory Follicular Lymphoma Treatment$

source: pixabay.com

Priority Review Granted for Relapsed and Refractory Follicular Lymphoma Treatment

Post author:Sunniva Bean
Post published:February 26, 2020
Post category:Rare Disease

According to a press release from Epizyme, Priority Review has been granted for tazemetostat (Tazverik), a drug used to treat relapsed or refractory follicular lymphoma (FL) for patients whose symptoms…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More